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     The plethora of studies indicated that there is a cross talk relationship between harmaline and 
serotonergic (5-HT) system on cognitive and non-cognitive behaviors. Thus, the purpose of this study is 
assessment the effects of CA1 5-HT4 receptor on memory acquisition deficit induced by harmaline. 
Harmaline was injected peritoneally, while 5-HT4 receptor agonist (RS67333) and antagonist (RS23597-
190) were injected intra-CA1. For memory measurement,a single-trial step-down passive avoidance 
apparatus was used. The data revealed that pre-training injection of higher dose of harmaline (1 mg/kg), 
RS67333 (0.5 ng/mouse) and RS23597-190 (0.5 ng/mouse)decreased memory acquisitionprocess in the 
adult mice. Moreover, concurrent pre-training administration of subthreshold doseof RS67333 (0.005 
ng/mouse) orRS23597-190 (0.005 ng/mouse)with subthreshold dose of harmaline (0.5 mg/kg, i.p.)intensify 
impairment of memory acquisition. All above interventions did not change locomotion and tail flick 
behaviors. In conclusion, the results demonstrated that the synergistic effect between both CA1 5-HT4 
receptor agonist and antagonist with impairment of memory acquisition induced by harmaline, indicating a 
modulatory effect for CA1 5HT4 receptor on Harmaline induced amnesia.  
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INTRODUCTION 
    There are severities of studies about 
involvement of serotonergic (5-HT) system in 
cognitive and non-cognitive behaviors.For 
instance a modulatory effect on stress, anxiety, 
food intake, pain perception, rhythm, learning and 
memory behaviors, inasmuch as dysfunction of 
serotonergic system can induced posttraumatic 
stress disorder, anxiety, and depression [1-5], 
which are often accompanied by impairment of 
learning and memory [6-8]. In this line some 
investigations demonstrated that 5-HT has a 
crucial role for learning and memory formation 
process via interaction on multiple receptor 
subtypes. For instance, it showed that blockade or 
activation of serotonergic system induced 
enhanced and impaired learning and memory 
process, respectively[9], while the opposite 
findings have also been reported[10, 11].It is clear 
that multiple 5-HT receptors have different 
responses on learning and memory, depending the 
drug, place of injection (focal or systemic), timing 
of drug injection and behavioral tests used[12]. 
The serotonergic axons from raphe nucleus 
(primarily localized of 5-HT cell bodies) projects 
into almost every brain region[13, 14], including 
hippocampus[6, 15, 16] and cerebral cortex[17], 
that have high expression of different 5-HT 
superfamily [18-21], indicating the important role 
of this system on cognition process such as 
learning and memory [18]. In according of 
structural, operational, and transductional 
properties of 5-HT receptors, seven classes for 5-
HT were classified, namely 5-HT1–
7superfamily[22, 23]. In among of these receptors 
5-HT3 receptor is a ligand-gated ion channel, 
while others are G-protein coupled receptor[22, 
23].  
Among of 5-HT receptors 5-HT4 receptor has a 
relatively high expression in the limbic system 
and a critical role for learning and memory 
process[24]. This receptor seems that has variety  




responses on different stages of memoryformation 
(acquisition, consolidation and retrieval). It seems 
that activation of this receptor induced a positive 
effect on the acquisition phase. The effect 5-HT4 
on memoryconsolidation is very variation 
dependent the method of injection and memory 
assessment[25-27]. About the memory retrieval a 
study revealed that 5-HT4receptor did not alter 
this memory state [25].It showed that activation 
of 5-HT4 receptor via systemic infusion increased 
LTP phenomenon in the CA1 and dentate gyrus 
regions[28, 29]. Monoamine oxidase A (MAOA), 
as a key enzyme in for serotonergic 
system,degrades the concentration level of 5-HT 
in the several parts of brain such as 
hippocampus[30, 31].  
β-carbolines are a class of alkaloids which have 
elicited considerableresearch interest [32, 33]. β-
carbolinesconsistof an indole nucleus and a 
pyridine ring[32, 34] that depending upon their 
degree of ring saturation can be dividedinto three 
structural groups: (a)harmane; (b)harmalane; and 
(c) the harmaline[32]. These compounds are 
endogenously produce and exist in normal body, 
such asblood plasma, heart, kidney, liver and 
brain tissue[35-37]. The biological significance of 
β-carbolines has been suggestedto have 
neuroprotective properties as well as cytotoxic 
properties [32, 37-39], excitation and euphoria 
[40, 41],analgesic effects[42], anticancerous and 
antibioticproperties[43, 44]. Some investigations 
indicated that β-carbolines bind with high affinity 
toa variety of different targets including MAOA, 
MAOB, benzodiazepine, imidazoline, dopamine 
and 5-HT receptors[45-49]. β-carbolines by 
inhibition of MAOA or MAOBincrease the 
extracellular norepinephrine, dopamine and 5-HT 
levels in several brain regions[34, 35, 50]. As 
regards β-carboline could enhance 5-HT levels in 
several brain area through inhibition of MAO 
reuptake system and considering the role of β-
carbolines[51], 5-HT receptors[52-57], and 
hippocampus[58-60], in memory process, in the 
present study, the effects of harmaline on memory 
acquisition/exploratory behaviors/pain response 
and involvement of 5-HT4 receptors on these 
behaviors in the step-down passiveavoidance, 
open field and tail flick tests in mice have been 
investigated.  
 
MATERIALS AND METHODS 
Animals 
    Male NMRI mice weighing 25–30 g 
obtainedfrom the University of Tehran (Tehran, 
Iran) were used. Animals were housed in groups 
of 10 in plastic cages and maintained at a 
controlled temperature of 22±2 °C under a 12/12-
h light/dark cycle with water and food freely 
available except during the limited times of 
experiments. Ten animals were used in each 
group and each mouse was used once only. 
Behavioral tests were done during the light phase 
of the light/dark cycle. The investigation was 
approved by the Ethics Committee of the Faculty 
of Science of the University of Tehran which 
corresponds to the national guidelines for animal 
care and use.  
Stereotaxic surgery 
    Mice were anaesthetized using a solution 
containing ketamine hydrochloride (50 mg/kg) 
plus xylazine (5 mg/kg) and positioned in a 
stereotaxic frame (Stoelting Co, Illinois, USA). 
Then, the skin was incised and skull was cleaned. 
Next, two stainless-steel guide cannulae (8 mm 
length, 22 gauge) were bilaterally implanted 1 
mm above the dorsal portion of the dorsal 
hippocampus (CA1). The following coordinates 
were used based on the Paxinos and Franklin 
atlas) [61]. Stereotaxic coordinates for the CA1 
area of the dorsal hippocampus were 
anteroposterior (AP)=-2 mm from bregma, 
mediolateral (ML) ±1.6 from the sagital suture 
and dorsoventral (DV)= -1.5 mm from the skull 
surface. Cannulae were secured to the bone with 
dental acrylic cement. A stylet was presented into 
the guide cannula to prevent possible obstruction. 
All mice were allowed about 5-7 days to recover 
from surgery and from the effect of the anesthetic 
agents[62, 63].  
Memory testing and apparatus 
     The inhibitory avoidance apparatus comprised 
of a wooden box (30×30×40 cm
3
) with a floor 
which consisted of parallel stainless steel rods 
(0.3 cm in diameter, spaced 1 cm apart). A 
wooden platform (4×4×4 cm
3
) was set in the 
center of the grid floor. Electric shocks (1 Hz, 0.5 
s and 50 VDC) were delivered to the grid floor 
via an isolated stimulator (Grass S44, Quincy, 
MA, USA).  




For testing, each mouse was gently placed on the 
wooden platform. When the animal stepped down 
from the platform and located all its paws on the 
grid floor, intermittent electric shocks were 
delivered continuously for 15 s. This training 
method was carried out among 9:00 a. m. and 
2:00 p.m. Twenty-four hours after training, each 
animal was located on the platform again, and the 
step-down latency was measured with a stop-
watch as passive avoidance behavior. An upper 
cut-off time of 300 s was set. The retrieval test 
was also carried out among 9:00 a. m. and 2:00 p. 
m[64, 65].  
Measurement of locomotor activity 
     The locomotion apparatus (BorjSanat Co, 
Tehran, Iran)comprised of clear perspex container 
box (30 cm × 30 cm × 40 cm high). The apparatus 
has a gray perspex panel (30 cm × 30 cm × 2. 2 
cm thick) with 16 photocells which 
separatedthebox to 16 equal-sized squares. 
Locomotor activity was recorded as the number of 
crossings from one square to another during 5 
min[66-68].  
Tail flick test 
    The tail flick test is a test of the pain responsein 
animals, alike to the hot plate test. It is used in 
basic painexamination and to measure the 
effectiveness of analgesics, through observing the 
reaction to heat. It was first presentedby[66, 69, 
70]. A light beam is focused on the animal's tail 
and a timer starts. Once the animal flicks its tail, 
the timer stops and the recorded time is a measure 
of the pain threshold. This behavior testing was 
done 5 min after training.  
Drugs 
    The drugs used in the present study were 
Harmaline (1-methyl-7-methoxy-3, 4-dihydro-
bcarboline)from Sigma (St. Louis, MO), 5-HT4 
receptor agonist (RS67333)and 5-HT4 receptor 
antagonist (RS23597-190) from (Tocris 
Bioscience United Kingdom). The time 
ofadministration and doses of drugs used in the 
experiments were chosenaccording to pilot studies 
and publishedwork in scientific literature[33, 34, 
64, 71]. The compounds were tested at doses: 
harmaline:0.25, 0.5 and 1mg/kg, RS67333: 0.005, 
0.05 and 0.5 ng/mouse, RS23597-190: 0.005, 0.05 
and 0.5 ng/mouse. Harmaline was dissolved in 
sterile0.9% saline solution and the compound was 
stirred for 1h beforeobtaining the final solution; 
other drugs were dissolved in 0.9% saline, just 
before the experiments.  
Drug treatment 
    For drug administration, the animals were 
restrained gently by hand; the stylets were 
removed from the guide cannulae and substituted 
by 27-gauge infusion needles (1mm below the tip 
of the guide cannulae).  
The injection solutions were administered in a 
total volume of 1 μl/mouse (0.5 μl in each side) 
over a 60 s period, manually. Injection needles 
were left in place for an extra 60 s to facilitate the 
diffusion of the drugs[71, 72]. The protocol has 
been illustrated in Table 1.  
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    We chose to analyze data using the Kruskal-
Wallis nonparametric one-way analysis of variance 
(ANOVA) followed by a two-tailed Mann-
Whitney’s U-test for because individual variations 
in step-down apparatus data. The median as well as 
interquartile ranges of the step-down latencies were 
recorded for ten mice in each experimental group. 
One/two way ANOVA followed by post-hoc test 
was used for statistical evaluation in the tail flick 
and open filed tasks. In all evaluations p<0.05 was 
considered statistically significant. All statistical 
analysis results have been summarized in the table 
2. 
Experiment1: effects of pre-training 5-HT4 drugs 
administration on memory acquisition 
    In this experiment, eight groups of mice were 
used. Four groups of animals received saline 
(1µl/mouse) or different doses of RS67333 (0.005, 
0.05 and 0.5 ng/mouse)5 min before training. The 
other four groups received saline (1 
µl/mouse)ordiverse doses of RS23597-190 (0.005, 
0.05 and 0.5 ng/mouse)5 min prior training.  
Experiment2: effects of pre-training 5-HT4 
receptor drugs administration on memory 
acquisition under the disruptive influence of 
harmaline 
    In this experiment, twelve groups (three arms) of 
mice were used. The animals received saline (1 
µl/mouse) or different doses of harmaline (0.25,  
0.5 and 1mg/kg; i.p.)15 min before training. These 
mice received intra-CA1 pre-training saline 
(1µl/mouse, for groups), subthreshold does of 
RS67333 (0.005ng/mouse, for groups) or 
RS23597-190 (0.005 ng/mouse, for groups) 5 min 
earlier training.  
Histology 
    Histological results were plotted on 
representative sections taken from the mice brain 
atlas of Paxinosand Franklin(Paxinos and Franklin, 
2001)[61][61]. Cannulae were implanted into the 
CA1 regions of dorsal hippocampus of a total of 
214 mice, however only the data from 200 animals 
with correct cannulae implants were included in 
statistical analyses.  
 
RESULTS 
Effects of pre-training intra-CA1 administration 
of 5-HT4 drugs on memory acquisition, 
locomotor activity and tail flick 
Kruskal-Wallis and Mann-Whitneydatadisplays 
that the infusion of RS67333 (0.5ng/mouse, figure 
3A; left panel) and RS23597-190 (0.5ng/mouse, 
figure 1A; right panel), 5 min before training, 
reduced memory acquisition. In addition, one-way 
ANOVA postulates that all interventions did not 
alter locomotor activity and tail flick behaviors 
(figure 1B and C; left panels for RS67333, 
meanwhile figure 1B and C; right panels for 
RS23597-190). 
 
Table 2. describe Kruskal–Wallis and one/two-way ANOVA analyses results for all experimental groups.  
Step-through latency(panel A) 




























































































































































































Figure 1. the effects of pre-training intra-CA1 administration of saline, RS67333 and RS23597-190 on memory acquisition, 
locomotor activity and tail flick. A left and right panels exhibit the effects of pre-training administration of RS67333 (0.005, 
0.05 and 0.5 ng/mouse) and RS23597-190 (0.005, 0.05 and 0.5 ng/mouse) on memory acquisition, respectively. Test session 
step-down latencies are expressed as median and quartile for 10 animals. Similarly, locomotor activity in panel B was 
examined 5 min after memory testing and tail flick in panel C was tested 5 min after training. Each bar is mean±S.E.M. 
**P<0.01 when compared to saline/saline group.  
 
Effects of pre-training 5-HT4 receptor drugs 
administration on memory acquisition, 
locomotor activity and tail flick under the 
amnesia induced byharmaline 
    Kruskal-Wallis and Mann-Whitneyresults in 
according of harmaline-treated groups exhibit that 
a subthreshold dose of RS67333 (0.005 ng/mouse, 
figure 2A, middle panel) or RS23597-190 (0.005 
ng/mouse, figure 2A, right panel)potentiated 
memory impairment induced by harmaline. 
Moreover, two-way ANOVA postulates that these 
interventions did not alter both locomotor activity 
(figure 2B; middle panel for RS67333, meanwhile 
figure 2B; right panel for RS23597-190) and tail 
flick (figure 2C; middle panel for RS67333, 
meanwhile figure 2C; right panel for RS23597-
190) behaviors.  






Figure 2. the effects of 5-HT4 receptor drugs on memory acquisition, locomotor activity and tail flick in the present and 
absence of harmaline. Figure 4A indicates the effects of pre-training infusion of harmaline (0.25, 0.5 and 1 mg/kg, i.p.; left 
panel) on animals which were trained under the effect of saline (1 µl/mouse; intra-CA1; left panel), RS67333 (0.005 ng/moue, 
intra-CA1; middle panel) or RS23597-190 (0.005 ng/mouse, intra-CA1; right panel). Test session step-down latencies are 
expressed as median and quartile for 10 animals. Furthermore, locomotor activity in panel B was measured 5 min after 
memory testing and tail flick in panel C was tested 5 min after training. Each bar is mean±S. E. M. ***p<0.001 when 









    The data revealed that pre-training intra-CA1 
injection of higher dose of 5-HT4 receptor agonist 
(RS67333) and 5-HT4 receptor antagonist 
(RS23597-190)impaired memory acquisition by 
itself, while did not alter locomotion and tail flick 
behaviors. The previous reports indicated that 5-
HT receptors depletion or activation of 
serotonergic system (i.e., tryptophan) impaired 
[74] memory formation process respectively, 
indicating direct participation of 5HT in learning 
and memoryformation[75].The responses of 5-HT 
receptors on learning and memory are very 
variable, because: 1- differentialaffinity from 5-
HT to its receptors[76] and 2- expression of 5-HT 
receptors on pre- and postsynaptic membranes of 
neurons[75, 76]. Both of these points can be 
mention as two critical factors inlearning and 
memory mechanisms[75, 76]. 5-HT4 receptors 
displays constitutive (ligand independent) 
activity, even if it contributes to function of the 
receptor only in a small extent. This activity 
clarifies the differences between expected and 
observed effects of agonists and antagonists of 5-
HT4 receptors. Some expected agonists shown 
rather silent or antagonistic effects depending on 
the level of ligand independent activity [77]. In 
consistent our data, some evidences revealed that 
5-HT4 receptor agonist [25] and antagonist [78] 
impaired memory. Some studies indicated that 5-
HT4 agonists enhance learning and memory[79-
82], or has no effect onmemory[12]. Therefore, 
the actual effect of 5-HT receptors on memory 
formation process has remained unclear in order 
to many contradictory findings. It seems that 
different brain regions, systemic or intra-focal 
injections, nature and degree of difficulty of 
behavioral tasks induced a critical role for the 
effect of 5-HT on learning and memory [57, 83-
85]. Moreover, the data revealed that pre-training 
systemic infusion of harmaline reduced memory 
acquisition, while did not change locomotion and 
tail flick behaviors. Harmaline induce several 
effects on cognitive and non-cognitive behaviors, 
includingeuphoria[40] and impair both associative 
and motor learning[32, 34, 50]. On the other 
hand, several report showed that harmaline 
improved learning and memory[32, 50]. It seems 
that the doses of drugs and route/methods of 
injections are very important for the effects of 
these compounds [50]. A report showed that 
harmaline decrease current of voltage-gated 
calcium channel, herein decrease neuron 
excitation. In the synaptic communication, 
calcium has a vital role, which controlling many 
cellular processes, inasmuch as increase of 
sytoplasmic calcium level concentration 
stimulates cellular signaling pathways involved in 
memory processes[32]. In conclusion, we can 
propose that the memory acquisition deficit 
induced by harmaline is in order to decrease 
calcium level and reduction of neuron excitation.  
In continue of this study, we assess the effect of 
5-HT4 receptors on harmaline induced avoidance 
memory deficit. The present study indicated that 
RS67333 and RS23597-190 strengthen amnesia 
induced by harmaline. It seems that harmaline by 
reducing neuron excitation[32], and 5-HT4 agents 
via constitutive (ligand independent) activity [77], 
causes impairment of memory acquisition. Since, 
co-administration of harmaline and 5-HT4 agents 
impaired memory acquisition; we proposed that 
these drugs have a synergistic effect on memory 
acquisition. However, further experiments are 
required to clarify the exact mechanisms 
involved, but it seems that harmaline induced its 
interaction effect via two mechanisms: 1-directly 
binding to 5-HT receptors[86] and 2-enhancement 
of extracellular concentration 5-HT levels via 
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